Focus on the research and development of innovative/nerve therapeutic solutions based on human gut microbes and immunity
Focusing on the development of innovative therapeutic solutions based on human gut microbes and immunity
Core Business
The company's core business is the development of intestinal bacteria drugs
Immunotherapy with human gut microorganisms
Development of clinical therapeutic solutions, including metabolic diseases, antineoplastic, inflammatory bowel disease and autoimmune diseases
Marked as the largest immunomodulatory functional strain developer in China and internationally.
Top International Gut Microbes and
Immunology Researcher-led Start-up Company
Ibiome Biology Co., Ltd. focuses on the development of innovative therapeutic solutions based on human gut microbes and immunity and is dedicated to the development of microbial-regulated immunotherapy solutions for tumors, autoimmune diseases, metabolic diseases and neurological disorders.
|
|
Professional R&D team
Ibiome Biology Co., Ltd. is a biotechnology company focused on innovative research and development of human gut microbes and is also a startup company led by top international gut microbiology and immunology researchers. The core R&D team consists of scientists from Yale University, Harvard Medical School, University of Science and Technology of China and other top international universities.
News
On March 12, 2024, Prof. Shu Zhu and Prof. Wen Pan's research group co-published the article Bile acids modified by the intestinal microbiota promote colorectal cancer growth by Immunity in the School
2024-03-13
Address: 16th Floor, Building E, Intelligent Equipment Technology Park, No. 3963, Susong Road, Economic and Technological Development Zone, Hefei City
Tel: 0551-63813386
Email: hr@ibiome.com.cn